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A vagal nerve stimulator (VNS) is a device designed to
prevent seizures in patients with drug-refractory epilepsy by
providing high-frequency (20–30 Hz) electrical stimulation
of the left vagus nerve, activating vagal nerve afferent ﬁbers
that carry signals to the brain and reduce seizure activity.
Similar to a cardiac pacemaker, the device generator is
implanted in the left subpectoral area. A single lead is then
attached to the left vagus nerve in the patient’s neck with a
cuff, which provides pulsatile electrical stimulation. The
device provides cyclical electrical stimulation every 30–300
seconds, and output can be increased by application of a
magnet to the chest wall to abort a seizure for patients who
experience premonitory symptoms.Case Report
A 23-year-old male with refractory epilepsy from frequent
complex partial seizures since the age of 4 years, which was
well-managed with a VNS device (model number 103,
Cyberonics, Houston, TX) that had been implanted 6 years
earlier and stable doses of lacosamide, levetiracetam, and
felbamate, presented to an outside hospital with chest pain,
dizziness, and nausea of 1-day duration, with onset while
doing manual work. On presentation, the patient was found
to be hypotensive and in ventricular tachycardia at 230 beats
per minute. Urgent electrical cardioversion was performed in
the emergency room; a single 200-J shock restored normal
sinus rhythm. Immediately thereafter, the patient began to
experience cyclic episodes of complete atrioventricular (AV)
block resulting in long pauses, which were associated with
lightheadedness and cough. The patient was transferred to
our facility for a higher level of care and management of
these recurrent episodes of ventricular asystole.KEYWORDS Vagal nerve stimulator; Asystole; Ventricular tachycardia;
Epilepsy; Device malfunction (Heart Rhythm Case Reports 2016;2:388–390)
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).On arrival, the patient appeared to be in distress, and
telemetry showed periods of ventricular asystole resulting from
sinus slowing with transient complete AV block (Figure 1)
lasting 10–15 seconds and occurring every 78 seconds. The
patient felt a prodrome to these episodes, followed by light-
headedness, chest discomfort, and urge to cough, and then
resolution with a return to normal sinus rhythmwith normal AV
conduction. Given the patient’s VNS and recent cardioversion,
and the apparent vagal mechanism of asystolic episodes, the
VNS device was promptly interrogated, showing programming
settings and parameters that were unchanged from the previous
interrogation 15 months prior (1.5-mA output, 25-Hz signal
output with pulse width 250 microseconds, 14-second signal
ON, 66-second signal OFF, magnet output 1.75 mA, magnet
ON time 60 seconds). Immediately following the deactivation
of the device, no further asystolic episodes occurred. Of note,
providers at the outside facility had attempted to disable the
stimulator by application of a magnet, which does not result in
inhibition of therapy as in implantable cardioverter-
deﬁbrillators but actually increased the vagal stimulation output
of the device, which likely prolonged the episodes of asystole.
Further evaluation of the patient revealed a troponin level of
56 ng/mL and globally reduced left ventricular ejection fraction
of 45%. Laboratory data reports from the outside hospital
revealed a magnesium concentration of 0.9 mg/dL, which
perhaps contributed to the initial presentation with ventricular
tachycardia. During hospitalization at our institution, there were
no further electrolyte imbalances. The results of an extensive
workup including cardiac positron emission tomography imag-
ing did not reveal structural cardiac abnormalities. Left
ventricular function returned to normal by the time of discharge,
and his initial reduction in function was attributed to cardiac
stunning from prolonged ventricular tachycardia and external
cardioversion. An implantable cardioverter-deﬁbrillator for
secondary prevention was implanted in the right chest wall
because the VNS already occupied the left side (Figure 2). The
patient’s VNS remained disabled, and his epilepsy was
managed medically, with good control of his seizures.Discussion
We present a case of cyclic asystole characterized by high-
degree AV block due to overstimulation of the vagus nervepen access article under the CC BY-NC-ND license
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Figure 2 A posterioanterior chest radiograph that was obtained following
the implantation of a dual-chamber implantable cardioverter-deﬁbrillator in
the right chest. The vagal nerve stimulator is seen in the left subpectoral area
with a thin lead (red arrows) traversing up to the left vagal nerve in the neck
to which is it is attached.
KEY TEACHING POINTS
 Malfunction of a vagal nerve stimulator can
manifest as overstimulation of the parasympathetic
nervous system, resulting in cyclic episodes of
asystole.
 Management of vagal-nerve-stimulator-induced
asystole is deactivation of the device with a
programmer.
 External placement of a magnet over a vagal nerve
stimulator is designed to increase stimulation
output to abort seizures. This action can
exacerbate episodes of asystole in a
malfunctioning device.
389Tomova et al Runaway Ventricular Nerve Stimulatorby malfunction of a VNS, likely from inadvertent external
cardioversion over the device. This is the ﬁrst case of its
nature, and this was reported to the US Food and Drug
Administration for review.
Malfunction of a VNS by external cardioversion or
deﬁbrillation has been cited by the manufacturer as a
potential complication, and it is recommended in the
physician’s manual that external cardioversion/deﬁbrillation
be performed at the lowest energy possible, with deﬁbrilla-
tion pads placed perpendicular to the generator and lead
system, and device function tested after deﬁbrillation is
applied.1 However, when patients present with unstable
ventricular arrhythmias or in cardiac arrest and little is
known about the medical history, inadvertent cardiover-
sion/deﬁbrillation over the device, which lies within the
shock vector of usual deﬁbrillation pad placement, can occur
as it did in this case. Whereas no apparent changes to the
programmed settings were noted, the causal relationship
between VNS malfunction and the episodes of asystole was
evident; evidence included cyclic episodes lasting the
approximate length of signal ON time (14 seconds), cycles
occurring at regular intervals approximately equal to that of
the combined signal ON and OFF times (66 and 14 seconds,
respectively), and the cessation of asystole episodes imme-
diately on disabling VNS output.
Contrary to the use of a magnet in deactivating tachy-
therapies of an implantable cardioverter-deﬁbrillator,Figure 1 A representative episode of asystole lasting 13 seconds, which was due
the patient’s vagal nerve stimulator.external magnet application over the VNS pulse generator
in the chest wall results in an increase in output and
stimulation of the vagal nerve. Depending on a patient’s
VNS model, programming, and seizure history, the applica-
tion of a magnet may augment output such as to provide 30–
60 seconds of continuous vagal nerve stimulation in an effort
to abort a seizure (in our patient’s case, 60 seconds at 1.75
mA compared with the baseline 1.5-mA output). On
implantation of the VNS, the patient is provided with a
magnet speciﬁc to the device, which is often worn around the
wrist similar to how a watch is worn. The patient is instructed
to “wave” the magnet over the chest wall at the prodrome of
a seizure. Similarly, a family member may be instructed to
use this magnet to abort a grand mal seizure in a patient.
The device manufacturer Cyberonics supplies program-
ming wands (Figure 3) to physicians authorized to care for
and manage these devices. These wands function similarly to
the programmers used for implantable cardiac devices: when
placed over the generator, these wands are able to wirelessly
gather information about the device settings and transmit
them to a computer. Reprogramming of settings, includingto high-degree atrioventricular block following electrical cardioversion over
Figure 3 A programming wand for the Cyberonics vagal nerve stimu-
lator. This tool connects to a tablet computer and is placed over the vagal
nerve stimulator to interrogate and program device settings.
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output to zero), can be performed through this programming
wand. Short of emergently removing the VNS surgically,
there are no other temporizing measures that can be under-
taken to halt or deactivate these devices in case of a
malfunction without access to a device wand.
VNS is a valuable treatment option in refractory epilepsy,
and it has been applied to other clinical entities, such as
depression. Given the proven beneﬁt of heart-rate-lowering
therapies such as beta blockers2 and ivadrabine3 in cardio-
myopathy patients, there is also signiﬁcant interest in
modulating the parasympathetic outﬂow to the heart and itsapplications in heart failure and arrhythmia prevention; so
far, however, clinical trials have not demonstrated signiﬁcant
beneﬁt.4,5
These devices have been shown to be relatively safe,
especially from a cardiovascular perspective, with only a few
case reports of severe bradycardia or asystole reported in the
literature.6,7 Both cases of late presentation of asystole, the
ﬁrst occurring 2 years and 4 months and the other 9 years
following implantation, were successfully managed by
discontinuing VNS therapies, as was done in this case. No
case of ventricular arrhythmia has been associated with VNS
therapy, and we believe these are unlikely to be associated in
this patient’s case. Generally, vagal stimulation provides a
protective effect on ventricular arrhythmias, though theoret-
ically torsade de pointes may arise from excessive vagal
stimulation and resultant bradycardia; this was not the
presenting rhythm in our patient’s case.Conclusion
Malfunction of a VNS, though rare, can occur after external
cardioversion/deﬁbrillation and may result in potentially life-
threatening episodes of asystole that can be managed by
discontinuing VNS therapies.References
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